GlassScriptPhysician profile
Yong He
NPI 1174555486
$3,622.26
in general payments reported to CMS, 2019-2025
24 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $115 · 2021: $248 · 2022: $539 · 2023: $913 · 2024: $909 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.73 | 2021-2024 | |
| Gilead Sciences, INC. | $895.06 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $218.60 | 2023-2025 | Acthar |
| Emd Serono, INC. | $179.23 | 2019-2020 | |
| Amarin Pharma, INC. | $159.16 | 2021-2023 | |
| Insmed, INC. | $144.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $136.27 | 2020-2021 | |
| Sirtex Medical INC | $134.48 | 2023 | Sir-Spheres Microspheres |
| Amgen INC. | $109.31 | 2022-2023 | Repatha, Otezla |
| Pfizer INC. | $84.54 | 2022-2025 | |
| Glaxosmithkline, LLC. | $78.11 | 2024-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $70.25 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $61.86 | 2023-2024 | Voquezna |
| Merck Sharp & Dohme LLC | $45.00 | 2024-2025 | Lagevrio |
| Exact Sciences Corporation | $38.45 | 2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.17 | 2024-2025 | Breztri, Farxiga |
| Vbi Vaccine (Delaware) INC. | $36.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.46 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.35 | 2023 | Jardiance |
| Biogen, INC. | $24.21 | 2020 | |
| Medline Industries LP | $22.93 | 2024 | |
| Astellas Pharma US INC | $22.32 | 2024 | Veozah |
| Shield Therapeutics INC | $20.85 | 2025 | |
| Ibsa Pharma INC. | $16.80 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.